Loading...
•
Mar 31, 2020
Immunic Q1 2020 Earnings Report
Announced financial results for the first quarter ended March 31, 2020 and highlighted recent activity.
Key Takeaways
Immunic reported its Q1 2020 financial results, highlighting the potential of IMU-838 as a therapeutic for SARS-CoV-2 infections and a successful $15.0 million financing.
IMU-838 demonstrated antiviral activity against SARS-CoV-2 in cellular assays.
Preparing a phase 2 clinical development program for IMU-838 as a potential treatment for COVID-19.
Bolstered financial position with a successful $15.0 million financing.
Expects top-line data from phase 2 trial of IMU-838 for RRMS in Q3 2020.
Immunic
Immunic
Forward Guidance
Immunic expects to be well funded through key, near-term milestones.
Positive Outlook
- Top-line data from phase 2 trial of IMU-838 for relapsing-remitting multiple sclerosis (RRMS), expected in the third quarter of this year.
- Results from the investigator-sponsored phase 2 trial for IMU-838 in primary sclerosing cholangitis (PSC), expected in early 2021.
- IMU-838 has potential as a therapeutic for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections.
- IMU-838 successfully demonstrated antiviral activity against SARS-CoV-2 at blood concentrations.
- Successful $15.0 million financing.